“The evidence is compelling.”

“Physicians understand the value.”

“Our KOLs are excited.”

“We’re getting strong feedback.”

All positive signals.

None necessarily mean: “I’d rather practice this way.”

A market can understand why the current standard needs to change. It can see the logic of a new one. It can believe the evidence supporting it.

And still choose what it already knows.

Positive response tells you the market sees value. It doesn’t tell you the market is willing to change how it practices.

That requires conviction.

In this briefing:

• Why positive market signals don’t necessarily lead to changed behavior
• The threshold between agreement and preference
• How CareDx made molecular surveillance a decision clinicians could trust
• The question to ask before you interpret enthusiasm as conviction

Markets don’t move from understanding a new approach to adopting it in a single leap.

First, the old way has to become difficult to defend. Then the market needs a new way to judge what good should look like.

But even then, the familiar choice still has an advantage: it’s known and trusted.

The market knows how to use it. What to expect from it. How to defend the decision if something goes wrong. Training, workflows, economics, precedent, and peer behavior can all reinforce the current practice—even when the alternative performs better.

Markets resist change for reasons that have little to do with whether your product is better.

That’s why strong evidence can coexist with slow adoption.

The question isn’t simply whether the market believes your evidence. It’s whether the market has enough confidence in the new approach to choose differently in practice.

Agreement doesn’t change behavior. Conviction does.

This is the third move in Belief Engineering: Build Conviction.

Conviction is what turns “I see it” into “I’d rather practice this way.”

Proof matters enormously here. But evidence is only persuasive in the context of what the market now believes matters.

Once the market has a new definition of success, evidence can show that your solution actually delivers against it.

Early experience shows what choosing differently looks like. Trusted peers make the unfamiliar choice easier to defend.

Together, they begin to change the risk equation.

Staying with the familiar no longer automatically feels like the safer decision.

CareDx faced exactly this challenge in heart-transplant surveillance.

For decades, endomyocardial biopsy had been deeply embedded in post-transplant care. The procedure was invasive and carried clinical burdens, but clinicians trusted it.

A blood-based approach could be easier for patients and still fail to change practice.

Because convenience wasn’t the real barrier. Trust was.

CareDx built HeartCare around two complementary molecular signals: AlloMap to assess immune activation and AlloSure-Heart to detect donor-derived cell-free DNA associated with graft injury.

The opportunity wasn’t simply to prove that molecular surveillance could generate useful information.

It was to give transplant teams enough confidence in that information to make a consequential clinical decision differently.

Prospective multicenter validation helped establish that confidence. Clinical experience allowed transplant programs to see how molecular surveillance performed in real patients. As transplant teams began incorporating those signals into surveillance decisions, the meaning of “safe” started to change.

A biopsy was no longer automatically the safer choice simply because it was the familiar one.

For appropriate patients, avoiding an unnecessary invasive biopsy could become the safer clinical decision.

By 2022, CareDx reported that HeartCare was being used by more than 90% of U.S. heart-transplant centers.

But penetration isn’t the most important signal.

The decision changed.

Clinicians were willing to use molecular surveillance to help determine whether and when a biopsy was necessary.

That’s preference becoming visible.

CareDx created enough confidence that avoiding an unnecessary biopsy became the safer clinical decision.

This is where commercial leaders need to be careful. Enthusiasm is easy to see. Preference is harder.

A physician saying the data are impressive is positive.

A KOL advocating for the new approach when you’re not in the room is stronger.

But a customer prioritizing it, choosing it, or changing a clinical decision because of it tells you something different.

Belief isn’t what the market says about your product. It’s what the market is willing to do differently because of it.

So before interpreting positive feedback as evidence the market is ready to choose differently, ask:

What evidence do we have that the market is beginning to choose differently—not just respond positively?

Interest tells you the market is paying attention.

Agreement tells you the new approach makes sense.

Preference tells you conviction is beginning to change decisions.

And that is the threshold that matters.

Conviction gets the market across an important line: “I’d rather practice this way.”

But preference still isn’t the finish line.

A market can prefer a new approach without having embedded it into everyday practice.

The final move is turning individual choices into routine behavior—until choosing the new standard no longer feels like choosing differently at all.

That’s where we go next.

Every market is already somewhere on the Market Belief Ladder. The Belief Engineering Framework maps the four belief shifts required to turn a new idea into a new standard of care.